Morgan Stanley Anticipates Rise In EW Share Price

“We believe the share price will rise in absolute terms over the next 60 days,” Morgan Stanley wrote in a report this morning regarding Edwards Lifesciences Corp.

. :Edwards will present key data from the PARTNER Cohort A trial at the American College of Cardiology meeting in New Orleans scheduled for April 3rd. Expectations are high following positive Cohort B data, but we still see upside to the stock. Our analysis suggests the trial is likely to show non-inferiority in its primary endpoint. “The potential to expand the addressable market into lower risk patients following success in PARTNER A should drive share price appreciation into 2H11 SAPIEN approval. We estimate that there is about a 70% to 80% or ‘very likely' probability for the scenario.” Edwards Lifesciences closed Wednesday at $85.15.